OR7-005 – Canakinumab in childhood colchicine resistant FMF
نویسندگان
چکیده
منابع مشابه
OR7-005 – Canakinumab in childhood colchicine resistant FMF
Introduction Familial Mediterranean Fever (FMF) is the most common hereditary autoinflammatory syndrome affecting >10,000 people in Israel. FMF is caused by mutations in the MEFV gene, which encodes for the pyrin protein that is part of the inflammation complex that activates IL-1b. Evidence from case reports/series and one controlled study supports IL-1 blockage as a potential treatment for FM...
متن کاملPW01-005 – Effects of placebo and colchicine on FMF patients
Results A total amount of 50 patients (22 girls, 28 boys) were included. The median age of the patients was 8.5 years (2.5-17.5). 78% of the patients suffered from fever attacks suggestive of FMF every 1-4 weeks. The attack interval of the remaining patients was more than one month. At the time of admission, the median values for ESR and CRP were; 24.5 mm/hr (1-100) and 2 mg/dl (0-31), respecti...
متن کاملQuality of life changes with canakinumab therapy in adults with colchicine resistant FMF
Introduction Familial Mediterranean Fever (FMF), the most common form of the hereditary autoinflammatory disorders, is characterized by recurrent attacks of fever along with serosal or synovial inflammation lasting usually 12 to 72 hours. FMF is associated with impaired functional ability, and the persistent disabling features and chronic pain, emotional and physical limitations can have a nega...
متن کاملP01-031 – Anakinra for colchicine resistant FMF
Methods We plan to include patients, agreeing with clinical and genetic diagnosis of FMF, who suffer from FMF attacks, at least once per month, in one of the sites commonly involved by FMF (Chest, abdomen, lower extremity large joints, and skin), despite treatment with colchicine 2 mg/ day or less (in case of colchicine intolerance). Involvement with other diseases relevant (vasculitis, spondyl...
متن کاملPW01-015 – Canakinumab in adults with colchicin resistant FMF
Introduction Familial Mediterranean fever (FMF) is associated with variations in the MEFV gene resulting in proteolytic activation of IL-1b through the inflammasome complex. There is no established treatment available for those resistant or intolerant to standard of care colchicine treatment. Canakinumab, a fully human selective anti-IL-1b monoclonal antibody with a half-life of ~4-weeks binds ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Rheumatology
سال: 2013
ISSN: 1546-0096
DOI: 10.1186/1546-0096-11-s1-a106